The clinical relevance of this finding relates to the fact that patients homogenous for low TPMT activity are at markedly greater risk for dose-related toxicity such as neutropenia during treatment with 6-mercaptopurine (Lennard et al., 1990). This evidence concerns the gene TPMT and neutropenia.